Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Other Non-Current Assets: 2013-2025

Historic Other Non-Current Assets for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $29.9 million.

  • Amphastar Pharmaceuticals' Other Non-Current Assets rose 26.21% to $29.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.9 million, marking a year-over-year increase of 26.21%. This contributed to the annual value of $26.0 million for FY2024, which is 0.32% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Other Non-Current Assets stood at $29.9 million for Q3 2025, which was up 6.29% from $28.1 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $29.9 million during Q3 2025, with a 5-year trough of $7.2 million in Q1 2021.
  • For the 3-year period, Amphastar Pharmaceuticals' Other Non-Current Assets averaged around $24.4 million, with its median value being $24.3 million (2024).
  • The largest annual percentage gain for Amphastar Pharmaceuticals' Other Non-Current Assets in the last 5 years was 217.43% (2021), contrasted with its biggest fall of 35.56% (2021).
  • Amphastar Pharmaceuticals' Other Non-Current Assets (Quarterly) stood at $16.7 million in 2021, then grew by 25.15% to $20.9 million in 2022, then climbed by 24.23% to $25.9 million in 2023, then climbed by 0.32% to $26.0 million in 2024, then increased by 26.21% to $29.9 million in 2025.
  • Its Other Non-Current Assets was $29.9 million in Q3 2025, compared to $28.1 million in Q2 2025 and $23.0 million in Q1 2025.